Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30377197.
- Also identified by DOI 10.1158/1078-0432.CCR-18-2819.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Systemic IL12 therapy has potent antitumor effects, but clinical delivery of this potent cytokine has been complicated by systemic toxicity. A novel strategy to deliver IL12 to the tumor microenvironment appears promising in a first-in-human study, appearing to stimulate tumor-specific adaptive immune responses with minimal systemic toxicity.<i>See related article by Strauss et al., p. 99</i>.
Medical subject headings
- Neoplasms
- State Medicine